STAT

We’ve updated STAT’s guidelines for op-ed submissions

We are tightening our standards for opinion pieces and our practices for vetting contributing writers.

At STAT, we are supremely proud of our journalism and our staff. We also value the trust of our readers.

So we have been distressed to learn in recent days that some outside contributors to our opinion section failed to disclose conflicts of interest or misled us about the true authorship and origins of their op-eds.

We have retracted one piece, as explained in . This experience prompted us to tighten

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Amylyx Pulling Its ALS Drug, GLP-1 Drugs For Parkinson’s, And More
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.

Related Books & Audiobooks